Zenas BioPharma, Inc. (ZBIO) Balance Sheet
As of 2026-06-30 (10-Q), Zenas BioPharma, Inc. (ZBIO) reported total assets of $701.7M, total liabilities of $454.6M and shareholders' equity of $247.1M, according to EquiReason's reading of its SEC filings. Cash and equivalents: $196.6M. Long-term debt: $223.0M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
ZBIOZenas BioPharma, Inc.Follow ZBIO — free
—
Price chart with a free account
- Market cap
- 1.8B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 18 Nov, in 25 days
| Line | FY2024 Dec 24 | FY2025 Dec 25 | Latest Jun 26 | Trend |
|---|---|---|---|---|
| Cash and equivalents | 319.7 | 110.6 | 196.6 | |
| Short-term investments | 31.0 | 232.6 | 446.5 | |
| Current assets | 355.9 | 351.2 | 653.8 | |
| Total assets | 370.0 | 383.6 | 701.7 | |
| Current liabilities | 57.3 | 62.6 | 65.8 | |
| Long-term debt | — | 78.6 | 223.0 | |
| Total liabilities | 57.5 | 141.5 | 454.6 | |
| Shareholders' equity | 312.5 | 242.1 | 247.1 |
USD millions · SEC XBRL
Zenas BioPharma, Inc. — questions
- How much cash does Zenas BioPharma, Inc. have?
- $196.6M in cash and cash equivalents as of 2026-06-30.
- How much debt does Zenas BioPharma, Inc. have?
- $223.0M of long-term debt as of 2026-06-30.
- What are Zenas BioPharma, Inc.'s total assets?
- $701.7M as of 2026-06-30.
- What is Zenas BioPharma, Inc.'s shareholders' equity?
- $247.1M as of 2026-06-30.
Every figure on this page comes from Zenas BioPharma, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.